CNBC April 30, 2024
Key Points
– Eli Lilly reported first-quarter adjusted profit that topped Wall Street’s expectations.
– The company also hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound.
– Zepbound reported $517.4 million in sales for the first quarter, even as most doses of the drug slipped into shortages in the U.S. that are expected to last through June.
Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street’s expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound.
The drugmaker now expects full-year adjusted earnings of $13.50 to $14.00 per share, up from previous guidance...
Today's Sponsors
Today's Sponsor